These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 33958157)
1. Management of Bladder Cancer: The First Inning of a New Era of Rapid Advances. Sonpavde GP Hematol Oncol Clin North Am; 2021 Jun; 35(3):xiii-xx. PubMed ID: 33958157 [No Abstract] [Full Text] [Related]
3. Recent developments in the biology and management of advanced bladder cancer. van Oosterom AT; Schrijvers D Eur J Cancer; 1995; 31A(5):838-9. PubMed ID: 7640075 [No Abstract] [Full Text] [Related]
4. Advances in intravesical drug delivery systems to treat bladder cancer. Kolawole OM; Lau WM; Mostafid H; Khutoryanskiy VV Int J Pharm; 2017 Oct; 532(1):105-117. PubMed ID: 28867449 [TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides in the treatment of bladder cancer. Glackin AJ; Gray SB; Johnston SR; Duggan BJ; Williamson KE Expert Opin Biol Ther; 2005 Jan; 5(1):67-77. PubMed ID: 15709910 [TBL] [Abstract][Full Text] [Related]
6. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Wallerand H; Reiter RR; Ravaud A Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279 [TBL] [Abstract][Full Text] [Related]
7. A critical analysis of the use of p53 as a marker for management of bladder cancer. Olumi AF Urol Clin North Am; 2000 Feb; 27(1):75-82, ix. PubMed ID: 10696247 [TBL] [Abstract][Full Text] [Related]
9. Promise of antisense oligodeoxynucleotide-based therapy for bladder cancer. Miyake H; Fujisawa M Expert Rev Anticancer Ther; 2008 Dec; 8(12):1851-4. PubMed ID: 19046104 [No Abstract] [Full Text] [Related]
10. p53 and treatment of bladder cancer. Cote RJ; Esrig D; Groshen S; Jones PA; Skinner DG Nature; 1997 Jan; 385(6612):123-5. PubMed ID: 8990112 [No Abstract] [Full Text] [Related]
11. Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin. O'Donnell M J Urol; 2006 Apr; 175(4):1197-8. PubMed ID: 16515958 [No Abstract] [Full Text] [Related]
12. Study increases molecular understanding of bladder cancer. Cancer Discov; 2014 May; 4(5):OF3. PubMed ID: 24795026 [No Abstract] [Full Text] [Related]
16. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. Zuiverloon TC; Theodorescu D Pharmacogenomics; 2017 Aug; 18(12):1167-1178. PubMed ID: 28745580 [TBL] [Abstract][Full Text] [Related]
17. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers. Millikan RE; Logothetis CJ J Natl Cancer Inst; 1998 Jul; 90(14):1028-9. PubMed ID: 9672249 [No Abstract] [Full Text] [Related]
18. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine. Espin Jaime MT; Moran Penco JM; Garcia Agundez JA; Caballero Loscos MJ; Sanjuan Rodriguez S; Botello Martinez F; Gomez de Tbjada R; Laguna Alvarez E; Benitez Rodriguez I Br J Urol; 1997 Jul; 80(1):151-2. PubMed ID: 9240200 [No Abstract] [Full Text] [Related]
19. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Highshaw RA; McConkey DJ; Dinney CP Curr Opin Urol; 2004 Sep; 14(5):295-300. PubMed ID: 15300150 [TBL] [Abstract][Full Text] [Related]
20. [Molecular markers of infiltrating cancer of the bladder]. Rigaud J; Tiguert R; Fradet Y Prog Urol; 2002 Nov; 12(5):1057-83. PubMed ID: 12536929 [No Abstract] [Full Text] [Related] [Next] [New Search]